Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPCT Regimen in Patients With Peripheral T-Cell Lymphoma (PTCL) Intolerant to Standard Chemotherapy
NCT07746245Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07746245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746245.